title: Abiraterone and its place in the treatment of metastatic CRPC.
abstract: An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.
authors.affiliation: Department of Medicine, Tulane Medical School, Box SL-42, 1430 Tulane Avenue, New Orleans, LA 70112, USA. osartor@tulane.edu
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.forename: Sumanta K
authors.initials: SK
authors.lastname: Pal
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002369:Castration; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D000737:Androstenols; D043823:Taxoids; D000077143:Docetaxel; C089740:abiraterone; D011241:Prednisone